Cullinan Therapeutics starts FDA New Drug Application for zipalertinib plus chemotherapy in NSCLC

Cullinan Therapeutics has begun an FDA New Drug Application for zipalertinib plus chemotherapy in non-small cell lung cancer, filed with partner Taiho. The submission follows initial Phase 3 REZILIENT3 data.

Detected & updated continuously · Source: Nebula